Hem/Onc Roundup: AI Predicts Breast Cancer, FDA Approves Pancreatic Cancer Treatment, and more

Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, researchers found that an artificial intelligence (AI) system better predicted breast cancer than humans, obesity is linked to cardiotoxicity in breast cancer, and more.

A global analysis found that an AI system was able to predict breast cancer more accurately than humans.

Bariatric surgery attenuates the risk of melanoma, according to a study published in JAMA Dermatology.

Obese patients with breast cancer who are receiving anthracyclines and/or trastuzumab have an increased risk of experiencing cardiotoxicity, according to a study published in PLOS Medicine.

The Food and Drug Administration granted approval for AstraZeneca and Merck’s Lynparza (olaparib) as a first-line maintenance therapy in adult patients with germline BRCA-mutated metastatic pancreatic cancer.

In case you missed it, more hem/onc headlines are featured below:

• Does Higher BMI Increase Survival with Atezolizumab in NSCLC?
• ACA Has Impacted Colorectal Cancer Diagnosis, Treatment in Younger Adults
• A New Anti-BCMA Therapy for Multiple Myeloma
• Proton vs. Photon Therapy in Cancer Patients: A Comparison